Orchid Pharma Seeks Approval for Rs 400 Crore Related-Party Purchases

Orchid Pharma Ltd is seeking approval for related-party purchases of up to Rs 400 crore in FY 2026-27.
The proposed transactions cover GCLE purchases from Otsuka Chemicals (India) Private Limited.

Reader Takeaway: Supply continuity is the key positive, while concentration on a single approved raw-material source remains a dependency.

What just happened

Orchid Pharma Ltd will place a material related-party transaction proposal before shareholders at its 33rd Annual General Meeting scheduled for September 29, 2026.

The company is seeking approval to purchase goods worth up to Rs 400 crore from Otsuka Chemicals (India) Private Limited during FY 2026-27.

The purchases relate to GCLE, a key raw material used in bulk drugs and formulations.

Why this matters

Orchid Pharma has stated that Otsuka Chemicals is currently its only approved source for GCLE. That makes the arrangement operationally important because continuity of supply directly supports manufacturing activity.

The company said the transactions are in the ordinary course of business and at arm's length. The arrangement itself is not new, but it has become a material related-party transaction under the current ownership structure following the takeover of operations by the Dhanuka group.

For investors, the Rs 400 crore approval limit is significant because it highlights the scale of procurement expected from one related counterparty.

What changes now

The AGM will formalise shareholder approval for the FY27 transaction limit with Otsuka Chemicals.

The company expects the arrangement to support manufacturing continuity and economies of scale. At the same time, the reliance on a single approved GCLE supplier remains an operational concentration that investors may want to monitor.

Board and management update

Shareholders will also vote on the re-appointment of Mridul Dhanuka as Whole-time Director.

Arjun Dhanuka is proposed to be appointed as Whole-time Director for five years from September 3, 2026 to September 2, 2031. His proposed fixed salary is Rs 8 lakh per month, with a 10% annual increment and applicable perquisites.

The AGM agenda also includes ratification of Rs 3.50 lakh remuneration for cost auditor J Karthikeyan for FY 2026-27.

AGM and voting details

The AGM will be held at 12:00 noon IST through video conferencing or other audio-visual means.

Remote e-voting will open on September 26, 2026 at 9:00 a.m. and close on September 28, 2026 at 5:00 p.m. Attendance through VC or OAVM will count toward quorum.

What to track next

The immediate trigger is shareholder approval for the Rs 400 crore related-party purchase limit and the proposed director appointments.

Investors should subsequently watch actual procurement levels from Otsuka Chemicals, any changes in approved sourcing for GCLE and whether the current supply arrangement continues to support stable manufacturing operations.